482 assets in Prostate Cancer

Therapeutic assets addressing Prostate Cancer, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Degarelix Prostate Cancer	Bayer	P4	BBB (72)
AVOLVE Prostate Cancer	Masonic Cancer Center, University of Minnesota	P4	BB (71)
Flotufolastat F 18 Prostate Cancer	Washington University School of Medicine	P4	BB (71)
Flutamide Prostate Cancer	VA Office of Research and Development	P4	BB (68)
Goserelin Prostate Cancer	Bayer	P4	BB (68)
Prednisone Prostate Cancer	Mayo Clinic	P4	BB (68)
Abiraterone Prostate Cancer	Mayo Clinic	P4	BB (67)
Bicalutamide Prostate Cancer	Washington University School of Medicine	P4	BB (67)
Dexasone Prostate Cancer	Qilu Hospital of Shandong University	P4	BB (67)
Docetaxel Prostate Cancer	National Cancer Institute (NCI)	P3	BB (67)
Enzalutamide Prostate Cancer	University of Michigan Rogel Cancer Center	P4	BB (67)
Leuporelin Prostate Cancer	Mayo Clinic	P4	BB (67)
Nilutamide Prostate Cancer	VA Office of Research and Development	P3	BB (67)
Zoledronate Prostate Cancer	Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia	P4	BB (67)
Cabazitaxel Prostate Cancer	Alliance for Clinical Trials in Oncology	P4	BB (66)
Darolutamide Prostate Cancer	University of Chicago	P4	BB (66)
Gozetotide Prostate Cancer	University of Texas Southwestern Medical Center	P3	BB (66)
Mitoxantrone Prostate Cancer	Shanghai Jiao Tong University School of Medicine	P3	BB (66)
Sipuleucel-T Prostate Cancer	City of Hope Medical Center	P3	BB (66)
Finasteride Prostate Cancer	Turku University Hospital	P4	BB (65)
Fluorine (18F) Psma 1007 Prostate Cancer	Novartis Pharmaceuticals	P3	BB (65)
Prednisolone Prostate Cancer	AstraZeneca	P4	BB (65)
Relugolix Prostate Cancer	Baptist Health South Florida	P3	BB (65)
Aspirin Prostate Cancer	IRCCS Azienda Ospedaliero-Universitaria di Bologna	P4	BB (64)
Ctt-1057 Prostate Cancer	Novartis Pharmaceuticals	P3	BB (64)
Cyproterone Prostate Cancer	Bayer	P3	BB (64)
FCH Prostate Cancer	ITEL Telecomunicazioni Srl	P3	BB (64)
Histrelin Prostate Cancer	Mayo Clinic	P3	BB (64)
Marcaine Prostate Cancer	Memorial Sloan Kettering Cancer Center	P4	BB (64)
Tamsulosin Prostate Cancer	Turku University Hospital	P4	BB (64)
AXUMIN Prostate Cancer	Blue Earth Diagnostics	P4	B (63)
Indometacinum Prostate Cancer	Zhejiang University	P2	B (63)
Piflufolastat Prostate Cancer	Novartis Pharmaceuticals	P4	B (63)
Ptvg-Hp Prostate Cancer	University of Wisconsin, Madison	P2	B (63)
Rocuronium Ion Prostate Cancer	Memorial Sloan Kettering Cancer Center	P4	B (63)
Rosopatamab Prostate Cancer	Telix Pharmaceuticals (Innovations) Pty Limited	P2	B (63)
Tamoxifen Prostate Cancer	University Health Network, Toronto	P3	B (63)
Vipivotide Tetraxetan Prostate Cancer	Mayo Clinic	P4	B (63)
Adriamycin Prostate Cancer	University of California, San Francisco	P3	B (62)
Cyclophosphamide Prostate Cancer	Icahn School of Medicine at Mount Sinai	P3	B (62)
Diphenhydramine Prostate Cancer	Merck Sharp & Dohme LLC	P4	B (62)
Epirubicin Prostate Cancer	Icahn School of Medicine at Mount Sinai	P3	B (62)
Lidocaine Prostate Cancer	University of Washington	P4	B (62)
N-(5-ISOQUINOLINESULFONYL)-1,4-PERHYDRODIAZEPINE Prostate Cancer	baotai Liang	P2/3	B (62)
Pembrolizumab Prostate Cancer	Icahn School of Medicine at Mount Sinai	P3	B (62)
qlc5508 Prostate Cancer	Qilu Pharmaceutical Co., Ltd.	P3	B (62)
Apalutamide Prostate Cancer	Alianza multidisciplinar para la investigación de los tumores genitourinarios -GUARD	P3	B (61)
Capivasertib Prostate Cancer	VA Office of Research and Development	P3	B (61)
Durvalumab Prostate Cancer	OHSU Knight Cancer Institute	P2	B (61)
Etoposide Prostate Cancer	University of Washington	P3	B (61)

Showing 1 to 50 of 482 assets

PreviousPage 1 of 10Next